NuCana plc, a clinical-stage biopharmaceutical company, reported improved financial results for FY2024, with net losses decreasing to £19.0 million from £27.6 million in 2023. The company's cash position stood at £6.7 million as of December 31, 2024, down from £17.2 million the previous year. Share-based payment expenses decreased significantly to £1.6 million from £3.9 million YoY.The company continues to advance its pipeline, with NUC-7738 in Phase 2 trials for solid tumors and melanoma, and NUC-3373 progressing through Phase 1b/2 trials for solid tumors and lung cancer. Management has implemented cost control measures, reflected in reduced key management compensation from £6.0 million to £3.6 million in 2024.Looking ahead, NuCana has initiated strategic financial moves, including a post-period ATM program raising £0.5 million through ADS issuance. The company plans a share restructuring in April 2025, involving the subdivision of 151,923,897 ordinary shares. Risk management remains focused on currency exposure, interest rates, and credit risk, with over 99% of cash held in A-rated institutions.

NuCana plc, a clinical-stage biopharmaceutical company, reported improved financial results for FY2024, with net losses decreasing to £19.0 million from £27.6 million in 2023. The company's cash position stood at £6.7 million as of December 31, 2024, down from £17.2 million the previous year. Share-based payment expenses decreased significantly to £1.6 million from £3.9 million YoY.The company continues to advance its pipeline, with NUC-7738 in Phase 2 trials for solid tumors and melanoma, and NUC-3373 progressing through Phase 1b/2 trials for solid tumors and lung cancer. Management has implemented cost control measures, reflected in reduced key management compensation from £6.0 million to £3.6 million in 2024.Looking ahead, NuCana has initiated strategic financial moves, including a post-period ATM program raising £0.5 million through ADS issuance. The company plans a share restructuring in April 2025, involving the subdivision of 151,923,897 ordinary shares. Risk management remains focused on currency exposure, interest rates, and credit risk, with over 99% of cash held in A-rated institutions.